Remetinostat Gel Promising for Basal Cell Carcinoma
Overall response rate of 69.7 percent seen with topical HDAC inhibitor; complete resolution observed for 54.8 percent of tumors on pathologic exam
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.